Comment on: Cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis.

Subjects

Subjects :

Female
Humans
Antibodies, Monoclonal economics
Bone Density Conservation Agents economics
Osteoporosis, Postmenopausal economics
Osteoporotic Fractures economics
RANK Ligand economics

Details

Language :

English

ISSN :

1433-2965

Volume :

23

Issue :

7

Database :

MEDLINE

Journal :

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA

Publication Type :

Editorial & Opinion

Accession number :

22086308

Full Text :

https://doi.org/10.1007/s00198-011-1830-8